ETF·NASDAQ
iShares Nasdaq Biotechnology ETF (IBB)
- Net assets
- $11.20B
- Expense ratio
- 0.44%
- Yield
- 0.16%
- 52-week range
- $154.62 $217.12
IBB ETF forecast today
Where IBB stands today, and what CleaRank Financial AI makes of it.
IBB at a glance
iShares Nasdaq Biotechnology ETF (IBB): Strong Buy, 80/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($208.02 and $184.07).
- Fund Expense ratio 0.44%, $11.2B in net assets, price up 35.0% over 1 year.
Figures as of October 27, 2026.
CleaRank Financial AI
CleaRank rates iShares Nasdaq Biotechnology ETF (IBB) Strong Buy, with a model score of 80/100.
The trend lifts the score most: the price is 15.23% above its 200-day average and 1.96% above its 50-day average, and the 50-day average is 13.01% above the 200-day. The 50-day average stands at $208.02 and the 200-day at $184.07. Over the past year the price rose 35.00%.
Only on CleaRank
Figures we compute ourselves from IBB's own price history. Tap one to see it in context.
IBB ETF price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $212.10 is 2.0% above the 50-day simple moving average of $208.02.Price above its 200-day average ›
The price is 15.2% above the 200-day simple moving average of $184.07.50-day average above the 200-day ›
The 50-day average ($208.02) is 13.0% above the 200-day average ($184.07), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 92% of its 52-week range, between $154.62 and $217.12.
IBB share price
Pick a period: each tab shows how far IBB has moved over it, to the last close.
Today's trading
Where IBB sits inside today's range and its 52-week range.
IBB fund facts and valuation
What the fund holds, what it costs and how it is valued.
Fund checks
3/5Expense ratio at or below 0.20% ›
The fund charges 0.44% a year, $44.00 on a $10,000 holding.Over $1B in net assets ›
Net assets total $11.2B.No sector above 35% of the fund ›
The largest sector, Healthcare, makes up 100.0% of the fund.Pays a distribution ›
The distribution yield is 0.16%.Price up over one year ›
The price rose 35.00% over the past year.
IBB Fund Facts
iShares Biotechnology ETF is an exchange-traded fund that provides broad exposure to U.S.-listed biotechnology companies. The fund is designed to track a biotechnology-focused index and typically holds a diversified basket of large, mid, and smaller biotechnology names, along with select life sciences tools and services companies that support drug discovery and research. Its portfolio includes firms involved in areas such as therapeutics, genetic medicine, diagnostics, and advanced research platforms.
Sector weights
Total returns, as the fund family reports them
| Period | IBB |
|---|---|
| YTD | 24.80% |
| 1 month | 0.67% |
| 3 months | 10.71% |
| 1 year | 46.08% |
| 3 years | 20.12% |
| 5 years | 5.69% |
| 10 years | 8.37% |
As of Oct 27, 2026, IBB has an expense ratio of 0.44%, $11.20B in net assets and a distribution yield of 0.16%.
Fund reference data as of Oct 27, 2026. Expense ratio and net assets are reported by the fund. The trailing returns are the fund family's own month-end total returns, with distributions included, so they can differ from the price changes elsewhere on this page.
Key statistics
The headline figures for IBB.
What the numbers say
CleaRank Financial AI's reading of IBB's holdings, performance and risks.
The iShares Nasdaq Biotechnology ETF (IBB) is dominated by Healthcare, which makes up 100.0% of the fund. With nearly all of its holdings in that single sector, IBB tends to move in step with it. IBB is a Health fund from iShares that launched on February 5, 2001.
The fund charges an expense ratio of 0.44%, meaning a $10,000 holding would pay $44.00 a year. Net assets stand at $11.2B, the distribution yield is 0.16%, and portfolio turnover is 27%.
Normal swings for IBB run at about 1.60% a day. Concentration matters here: Healthcare makes up 100.0% of the fund, so a setback in that sector would weigh on the whole.
IBB AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 57.2, in neutral territory.RSI above 50 ›
An RSI of 57.2 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of IBB
The score, the reasoning behind it, and what could move the price next.
IBB, the iShares Nasdaq Biotechnology ETF, is holding an upward trend with the price at $212.10. It sits 1.96% above its 50-day average of $208.02 and 15.23% above its 200-day average of $184.07. The price is at 92% of its 52-week range, 2.31% below the 52-week high of $217.12. Meanwhile, the 50-day average is 13.01% above the 200-day average.
Returns have been positive across every window shown. Over the past three months the price climbed 11.33%, over six months 26.39%, and over the past year 35.00%. Momentum tells a similar story in a calmer register: the 14-day RSI sits at 57.2, in the neutral zone, and the MACD line is positive.
- The two closest levels to watch are the 52-week high at $217.12, which sits above the price, and the 50-day SMA at $208.02, which sits below it.
- The 14-day RSI reads 57.2, in the neutral zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- Costs compound: at 0.44% a year, IBB charges $44.00 on every $10,000 invested.
IBB trades above its 50-day and 200-day moving averages ($208.02 and $184.07), which is what makes the trend up; losing the 50-day would be the first warning. The nearest level under the price is the 50-day SMA at $208.02.
The next level above the price is the 52-week high, at $217.12.
Technical indicators
Momentum and trend for IBB, from its daily closes.
As of October 27, 2026, with IBB at $212.10, its 14-day RSI is 57.2 (neutral territory), its 50-day simple moving average is $208.02 and its 200-day is $184.07.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What IBB moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, IBB's 1-year correlation of daily returns is +0.57 with S&P 500 (SPY), +0.48 with Nasdaq 100 (QQQ), +0.28 with Bitcoin (BTC) and +0.20 with gold (XAU).
IBB trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
IBB trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from IBB's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much IBB tends to move, against the market and on its own.
IBB price history and drawdowns
IBB's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.60% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 39.7%, from September 2021 to June 2022, regained by January 2026.Most 1-year holds ended higher ›
67% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $24,153, against $42,015 in the S&P 500 (SPY).
IBB Drawdowns & Recovery
As of October 27, 2026, IBB's worst peak-to-trough fall over the last 10 years with dividends reinvested was -39.7% (September 2021 to June 2022); it regained that peak by January 2026, 43 months after the low, and 67% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into IBB in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: IBB trailed the S&P 500 over this period: $24,153 against $42,015.
A $10,000 investment in IBB in October 2016 would be worth about $24,153 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to IBB, and which have not.
Strongest month, June: an average of +5.06%, up in 8 of 10 years.
Weakest month, March: an average of -2.78%, up in 3 of 10 years.
This month, October: has averaged -0.94%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, IBB's strongest calendar month has been June (average +5.06%, up in 8 of 10 years) and its weakest March (average -2.78%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
IBB price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in IBB, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in IBB today could grow to about $13,291 by 2030 in the base case, with a 90th-percentile outcome near $24,121 and a 10th-percentile outcome around $7,323. The simulation models price only; at today's 0.16% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
IBB 2030 Scenarios (Monte Carlo)
The same simulation in prices, year by year.
CleaRank's simulation projects a price near $282 for IBB by 2030 in the base case, from $212 today (1.3x over 4 years). The 10th-percentile path ends near $155. These are outcomes of a Monte Carlo simulation run on IBB's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $169 | $228 | $307 | |
| 2028 | $160 | $245 | $373 | |
| 2029 | $157 | $263 | $440 | |
| 2030 | $155 | $282 | $512 |
Method: a lognormal simulation of IBB's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
IBB ETF forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.